Is Transchem Ltd (TRANSCHEM) a good quality company?

Past 10 year’s financial track record analysis by Moneyworks4me indicates that Transchem Ltd is a below average quality company .

Is Transchem Ltd (TRANSCHEM) undervalued or overvalued?

The key valuation ratios of Transchem Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone .

What is Transchem Ltd (TRANSCHEM) share price return in the past 10 years?

Transchem Ltd share price has appreciated 25% annually (CAGR) over the past ten years.

Is Transchem Ltd (TRANSCHEM) a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Transchem Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.

What is the share price of Transchem Ltd (TRANSCHEM)?

Company share prices are keep on changing according to the market conditions. The current trading price of Transchem Ltd (TRANSCHEM) on 13-Apr-2026 16:59:59 at 16:59 is 156.15.

What is the market cap of Transchem Ltd (TRANSCHEM)?

Market capitalization is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 13-Apr-2026 at 16:59, the market cap of Transchem stood at Rs. 191.13 Cr.

What is the P/E ratio of Transchem?

The latest standalone P/E ratio of Transchem as of 13-Apr-2026 is 65.23.

What is the P/B ratio of Transchem Ltd (TRANSCHEM)?

The latest standalone P/B ratio of Transchem Ltd (TRANSCHEM) as of 13-Apr-2026 is 2.34.

What is the 52-week high and low of Transchem Ltd (TRANSCHEM)?

The 52-week high of Transchem Ltd (TRANSCHEM) is Rs. 194.25 and the 52-week low is Rs. 33.11.

What is the TTM revenue of Transchem Ltd (TRANSCHEM)?

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Transchem is Rs. 2.42 (Cr.).

Transchem Ltd (TRANSCHEM) Share Analysis – Quality, Valuation Zone & Price Trend & DeciZen Rating

Name: Transchem Ltd (TRANSCHEM)
Brand: Transchem

10 Year X-Ray :

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

Value Creation Index Colour Code Guide ⓘ

	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	TTM
ROCE % ⓘ	0.1%	-0.6%	-1.5%	2.1%	2.1%	49.7%	6.1%	3.8%	8%	9.1%	-
Value Creation Index ⓘ	-1.0	-1.0	-1.1	-0.9	-0.9	2.6	-0.6	-0.7	-0.4	-0.4	-
Growth Parameters ⓘ Growth Parameters Colour Code Guide ⓘ
Sales ⓘ	0	0	0	0	0	22.5	0	0	0.4	2.6	2
Sales YoY Gr.	-	NA	NA	NA	NA	NA	-100%	NA	NA	541.5%	-
Adj EPS ⓘ	-0.9	-1.1	-1.5	0.1	0.3	19.7	2.3	1	3.4	4	2.4
YoY Gr.	-	NA	NA	NA	135.7%	5878.8%	-88.1%	-56.8%	239.6%	16.3%	-
BVPS (₹) ⓘ	31.4	31	30.1	31	30	51.4	54.2	53.8	61.8	64.8	66.6
Adj Net Profit ⓘ	-1.1	-1.3	-1.8	0.2	0.4	24.2	2.9	1.2	4.2	4.9	3
Cash Flow from Ops. ⓘ	1.1	0.6	-19.8	10.3	-0.6	-27.7	21.9	1.2	-39.3	36	-
Debt/CF from Ops. ⓘ	0	0	0	0	0	0	0	0	0	0	-

CAGR ⓘ

CAGR Colour Code Guide ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	NA	NA	NA	541.5%
Adj EPS ⓘ	NA	64.6%	19.5%	16.3%
BVPSⓘ	8.4%	16.6%	6.2%	4.9%
Share Price	25%	54.7%	97.9%	335.4%

Key Financial Parameters ⓘ

Performance Ratio Colour Code Guide ⓘ

	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	TTM
Return on Equity % ⓘ	-2.9	-3.4	-4.9	0.4	1.1	48.5	4.4	1.9	5.9	6.3	3.6
Op. Profit Mgn % ⓘ	0	0	0	0	0	91.4	0	0	-423.4	-55.7	-19.9
Net Profit Mgn % ⓘ	0	0	0	0	0	107.5	0	0	1025.2	185.5	120.9
Debt to Equity ⓘ	0	0	0	0	0	0	0	0	0	0	-
Working Cap Days ⓘ	0	0	0	0	0	457	0	0	40,246	7,099	721
Cash Conv. Cycle ⓘ	0	0	0	0	0	1	0	0	183	209	718

Recent Performance Summary

Net Profit is growing at healthy rate in last 3 years 19.47%

Sales growth is good in last 4 quarters at 97.56%

Return on Equity has declined versus last 3 years average to 3.60%

Sales growth has been subdued in last 3 years 0.00%

	Standalone	Consolidated
TTM EPS (₹)	2.4	-
TTM Sales (₹ Cr.)	2.4	-
BVPS (₹) ⓘ	66.6	-
Reserves (₹ Cr.) ⓘ	69	-
P/BV ⓘ	2.34	-
PE ⓘ	65.23	-

From the Market
52 Week Low / High (₹)	33.11 / 194.25
All Time Low / High (₹)	2.55 / 194.25
Market Cap (₹ Cr.)	191
Equity (₹ Cr.)	12.2
Face Value (₹)	10
Industry PE ⓘ	24.4

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Sales	0	0	0	0	0	22	0	0	0	3
Operating Expenses ⓘ +	1	1	2	1	1	2	3	2	2	4
Manufacturing Costs	0	0	0	0	0	0	0	0	0	0
Material Costs	0	0	0	0	0	0	0	0	0	3
Employee Cost	0	0	0	0	1	1	1	1	1	1
Other Costs ⓘ	1	1	1	1	1	1	2	1	1	1
Operating Profit ⓘ	-1	-1	-2	-1	-1	21	-3	-2	-2	-1
Operating Profit Margin (%)	-	-	-	-	-	91.4%	-	-	-423.0%	-55.7%
Other Income ⓘ +	2	2	2	3	3	4	7	4	7	9
Exceptional Items ⓘ	0	0	0	0	0	0	0	0	0	0
Interest ⓘ	0	0	0	0	0	0	0	0	0	0
Depreciation ⓘ	1	1	1	1	1	0	0	0	0	0
Profit Before Tax ⓘ	0	-0	-1	1	1	25	4	3	6	7
Tax ⓘ	0	0	1	0	0	1	1	1	1	2
Profit After Tax	0	-0	-1	0	0	24	3	1	4	5
PAT Margin (%)	-	-	-	-	-	107.5%	-	-	1,025.2%	198.7%
Adjusted EPS (₹)	0.0	-0.2	-1.0	0.3	0.3	19.7	2.3	1.0	3.4	4.3
Dividend Payout Ratio (%)	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Equity and Liabilities
Shareholders Fund +	38	38	37	38	37	63	66	66	76	79
Share Capital ⓘ	12	12	12	12	12	12	12	12	12	12
Reserves ⓘ	26	26	25	26	25	51	54	54	63	67
Debt +	0	0	0	0	0	0	0	0	0	0
Long Term Debt	0	0	0	0	0	0	0	0	0	0
Short Term Debt	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
Trade Payables	0	0	0	0	0	0	0	0	0	0
Others Liabilities ⓘ	-0	-0	0	0	0	0	1	0	1	0
Total Liabilities ⓘ	38	38	37	38	37	63	67	66	76	80
Fixed Assets
Net Fixed Assets ⓘ +	7	6	5	4	4	0	0	0	0	0
Gross Block	38	7	7	6	6	0	0	0	0	0
Accumulated Depreciation	30	1	2	2	2	0	0	0	0	0
CWIP ⓘ	0	0	0	0	0	0	0	0	0	0
Investments ⓘ	28	30	10	6	4	9	9	8	9	2
Inventories	1	1	0	0	0	0	0	0	0	0
Trade Receivables	0	0	0	0	0	0	0	0	0	3
Cash Equivalents ⓘ	1	0	0	16	16	12	34	34	0	42
Others Assets ⓘ	0	0	21	12	13	43	24	23	67	33
Total Assets ⓘ	38	38	37	38	37	63	67	66	76	80

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Cash Flow From Operating Activity ⓘ +	1	1	-20	10	-1	-28	22	1	-39	36
PBT ⓘ	0	-0	-1	1	1	25	4	3	6	7
Adjustment ⓘ	1	1	1	1	1	-22	-0	-0	-0	-1
Changes in Working Capital ⓘ	0	-0	-21	9	-1	-29	19	-0	-44	32
Tax Paid ⓘ	0	0	-0	-0	-1	-1	-1	-1	-1	-2
Cash Flow From Investing Activity ⓘ +	-0	-2	20	6	1	23	1	-1	5	6
Capex	-0	-0	0	0	0	26	0	0	-0	1
Net Investments	-1	-2	20	5	1	-3	1	-1	5	5
Others ⓘ	0	0	0	0	0	0	0	0	0	0
Cash Flow From Financing Activity ⓘ +	0	0	0	0	0	0	0	0	0	0
Net Proceeds from Shares ⓘ	0	0	0	0	0	0	0	0	0	0
Net Proceeds from Borrowing ⓘ	0	0	0	0	0	0	0	0	0	0
Interest Paid ⓘ	0	0	0	0	0	0	0	0	0	0
Dividend Paid ⓘ	0	0	0	0	0	0	0	0	0	0
Others ⓘ	0	0	0	0	0	0	0	0	0	0
Net Cash Flow ⓘ	1	-1	-0	16	0	-5	23	0	-34	42

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Ratios
ROE (%)	0.12	-0.57	-3.18	0.82	1.1	48.44	4.44	1.87	5.94	6.74
ROCE (%)	0.12	-0.57	-1.47	2.07	2.12	49.69	6.05	3.79	7.99	9.12
Asset Turnover Ratio	0	0	0	0	0	0.45	0	0	0.01	0.03
PAT to CFO Conversion(x)	N/A	N/A	N/A	N/A	N/A	-1.17	7.33	1	-9.75	7.2
Working Capital Days
Receivable Days	0	0	0	0	0	0	0	0	365	216
Inventory Days	0	0	0	0	0	1	0	0	0	0
Payable Days	0	0	0	0	0	0	0	0	0	19

About Transchem Ltd

Transchem limited is a professionally managed, public limited company, the API manufacturing operations were started in 1993. The company is reputed as quality conscious manufacturer and exporter of specialized high quality API's and pharmaceutical intermediates.

The company is the largest producer of widest range of Anathematic API's (Anti-Parasitic) in the world, manufactured under one roof in WHO GMP accredited facility. It also offers specialized range of human use APIâ€™s.

The company is having four state of the art GMP approved facilities at multiple locations in India, with total production capacity of 500 MT per annum.

The company is one of the largest suppliers of Albendazole, Clorsulon, Diminazene Diaceturate, Toldimfos Sodium, Oxfendazole, Fenbendazole, Flubendazole, Mebendazole, Nitroxynil, Ramipril from India and can meet all the requiered technical and quality aspects of esteemed organizations and is now focusing on Anti-Hypertensive and Anti-Diabetic range of products.

Products and services offered by the company:

Services:

Contract Research Facility.
Custom Synthesis of Molecules.
Contract Manufacturing of API's as per GMP Guidelines.
Intermediates.
Veterinary Formulations.
Q.A. & Regulatory Support.

Product:

Anthelmintics

Albendazole USP / EP /BP
Ricobendazole (Albendazole Sulphoxide)
Mebendazole EP / BP / USP / POLY 'C'
Oxyclozanide BP VET
Closantel Sodium EP / BASE
Clorsulon USP
Nitroscanate
Fenbendazole EP/BP/BP VET
Oxfendazole BP VET / EP
Flubendazole EP / 98%
Nitroxynil BP VET
Rafoxanide BP VET
Triclabendazole
Praziquantel BP / USP

Veterinary API's

Diminazene Diaceturate B VET C
Quinapyramine Salts B VET C
Parvaquone
Toldimfos Sodium
Acepromazine Maleate BP VET
Butaphosphan
Flunixin Meglumine USP
Homidium Bromide / Chloride
Isometamedium

Ectoparaciticides

Cyromazine.
Cymiazole
S-Methoprene
Azamethiphos.

Human Use API's

Ramipril EP
Frusemide EP / BP / USP
Gabapentin USP
Cetirizine DI HCL EP/BP
Lamotrigine
Pentamidine Isetionate BP
Succinylcholine Chloride USP
Epinastine HCL
Nifuroxazide

Build a Stress-Tested Portfolio.

Our Sapphire Advisory uses the ABC Concept to ensure you never have to panic during a market correction.

Core Stocks

STABILITY

Booster Stocks

GROWTH

Amplifier Stocks

ASYMMETRY

● Conflict-Free ● SEBI Registered ● 15Y+ Track Record

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045
Compliance officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com Telephone: +91 98609 19463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com Telephone: +91 91758 99463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Transchem Ltd (TRANSCHEM) Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating

Transchem Share Price